Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid Diseases AND Hyperthyroidism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Thyroid Diseases AND Hyperthyroidism. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-005050-11 Sponsor Protocol Number: SeMMIviD Start Date*: 2019-03-08
    Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
    Full Title: Effects of Selenium and cholecalciferol on hyperthyroidism due to Graves' disease treated with methimazole: a randomized, clinical, open label, pilot trial
    Medical condition: Graves' disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020850 Hyperthyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003579-21 Sponsor Protocol Number: RAI2012 Start Date*: 2012-09-25
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: Effect of the withdrawal of anti-thyroid treatment on the iodide 123 kynetics used for the dosmetry before radioiodine therapy with 131I for autoimmune hyperthyroidism.
    Medical condition: Autoimmune hyperthyroidism (Graves-Basedow disease)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10043739 Thyroid gland disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001941-11 Sponsor Protocol Number: 2021-1798 Start Date*: 2021-09-09
    Sponsor Name:Rijnstate hospital
    Full Title: Ultrasound-guided radiofrequency ablation versus radioactive iodine as treatment for hyperthyroidism caused by solitary autonomous thyroid nodules.
    Medical condition: Patients > 18 years with (subclinical) hyperthyroidism caused by a solitary hyperactive thyroid nodules, either as a solitary hyperactive node in an otherwise normal thyroid gland or as a single hy...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004860 10043753 Thyroid nodule (toxic) LLT
    20.0 100000004860 10043791 Thyrotoxicosis from ectopic thyroid nodule LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001024-31 Sponsor Protocol Number: 08/S0501/31 Start Date*: 2008-08-27
    Sponsor Name:University of Oxford
    Full Title: A randomised controlled trial of iodide supplementation in preterm infants with follow-up at 2 years
    Medical condition: Transient hyothyroxinaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004860 10043710 Thyroid disorder NOS LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001455-42 Sponsor Protocol Number: NL56309.091.16 Start Date*: 2016-04-20
    Sponsor Name:Radboud Universitair Medisch Centrum
    Full Title: The influence of metformin and a hypocaloric diet on thyroid radioactive iodide uptake in healthy volunteers: a pilot study
    Medical condition: physiological thyroid function in terms of thyroid iodide uptake and thyroid hormone production knowledge can be extrapolated for treatment of thyroid diseases such as hyperthyroidism and thyroid ...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020855-29 Sponsor Protocol Number: E1496/09 Start Date*: 2009-10-16
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI MESSINA
    Full Title: Radioiodine ablation of post-surgical thyroid remnants by recombinant human TSH (rhTSH) in patients with moderately severe and severe Graves' orbithopathy (GO)
    Medical condition: Patients affected with moderately severe and severe GO
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    14.1 10014698 - Endocrine disorders 10043739 Thyroid gland disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000209-35 Sponsor Protocol Number: 7805 Start Date*: 2016-08-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism
    Medical condition: Graves' hyperthyroidism
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003515-38 Sponsor Protocol Number: GO-TXATD Start Date*: 2016-02-23
    Sponsor Name:Medical University of Vienna
    Full Title: Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) versus Thionamides (Anti-Thyroid Drugs) in Patients with Moderate-to-Severe Graves’ Ophthalmopathy - a 1-year Follow-up
    Medical condition: Graves' disease, hyperthyroidism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002127-26 Sponsor Protocol Number: BAFFI_14 Start Date*: 2015-10-13
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Randomized, single-blind, controlled study of the anti-BAFF antibody belimumab or methylprednisolone treatment in hyperthyroid Graves' disease (GD) and active orbitopathy (GO)
    Medical condition: GRAVES' ORBITOPATHY
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002894-27 Sponsor Protocol Number: IMVT-1401-2501 Start Date*: 2023-04-03
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD)
    Medical condition: Graves` disease
    Disease: Version SOC Term Classification Code Term Level
    26.0 10014698 - Endocrine disorders 10018706 Graves' disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001611-24 Sponsor Protocol Number: CAIN457ADE16 Start Date*: 2021-07-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, paralle...
    Medical condition: Active, moderate to severe thyroid eye disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022840-19 Sponsor Protocol Number: SEBA Start Date*: 2011-12-30
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: A monocentric, randomized, placebo-controlled double-blind clinical trial to assess the efficacy of Selenium in Morbus Basedow
    Medical condition: Morbus Basedow
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10004161 Basedow's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004676-35 Sponsor Protocol Number: RVT-1401-2001 Start Date*: 2019-10-23
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: ASCEND GO2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy
    Medical condition: Graves´Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001910-40 Sponsor Protocol Number: OPHT-120312 Start Date*: 2012-06-06
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: The effect of intravenous glucocorticoids on the tearfilm in eyes with thyroid-associated ophthalmopathy
    Medical condition: Thyroid-associated ophthalmopathy (TAO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10065624 Graves-Basedow disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005000-36 Sponsor Protocol Number: VGN-TED-301 Start Date*: 2022-07-12
    Sponsor Name:VasaraGen, Inc.
    Full Title: A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.1 10015919 - Eye disorders 10072802 Thyroid associated orbitopathy LLT
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002787-68 Sponsor Protocol Number: IMVT-1401-3201 Start Date*: Information not available in EudraCT
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002788-30 Sponsor Protocol Number: IMVT-1401-3202 Start Date*: 2023-07-13
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10015919 - Eye disorders 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005999-36 Sponsor Protocol Number: HZNP-TEP-402 Start Date*: 2022-05-24
    Sponsor Name:Horizon Therapeutics U.S.A., Inc.
    Full Title: A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005564-41 Sponsor Protocol Number: CCFZ533X2205 Start Date*: 2016-06-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label study to evaluate the safety and efficacy of 12 week treatment with CFZ533 in patients with Graves' disease
    Medical condition: Graves' disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10018706 Graves' disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002763-18 Sponsor Protocol Number: HZNP-TEP-301 Start Date*: 2018-02-22
    Sponsor Name:Horizon Therapeutics USA, Inc.
    Full Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC Trial)
    Medical condition: Active Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:36:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA